An observational study in Atrial Fibrillation (AF), Hypertension and Coronary Heart Disease (CHD), sponsored by Beijing Anzhen Hospital. Recruiting at 1 site in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-02.
Sponsored by Beijing Anzhen Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital — 25 open to participants now, 26 under way, 1 of them phase 3. Atrial Fibrillation · Beijing Anzhen Hospital.
Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2024, is one of 12 observational ones, reaches primary completion later than 21 of the 25 other live ones, and was the 23rd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →25 of the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Anzhen Hospital · Sites in China
Ages 80+
Beijing Anzhen Hospital · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 18–75
Beijing Anzhen Hospital · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30,000 is above the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 410 across the 24 interventional studies, 7,000 across the 12 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Anzhen Hospital is the lead sponsor of 194 studies on the registry; 103 are open to participants now.
6 of the studies in Atrial Fibrillation by Beijing Anzhen Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07411170Beijing Anzhen HospitalWearable Device-Assisted Remote Management in Atrial Fibrillation Complicated by Heart Failure: WARM-HF Trial | 2026-12 |
| NCT07541339Beijing Anzhen HospitalSafety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation | 2026-12-01 |
| NCT06791629Beijing Anzhen HospitalPulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation | 2026-12-15 |
| NCT06927908Beijing Anzhen HospitalCardiac Denervation in Aortic Arch Replacement | 2027-01-01 |
| NCT07095959Beijing Anzhen HospitalMarshall Vein Ethanol Infusion in Addition to Pulsed Electric Field Ablation Versus Pulsed Electric Field Ablation Alone for Paroxysmal Atrial Fibrillation | 2027-07-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective observational cohort study conducted in Qujiang District, Zhejiang Province, China, aiming to evaluate the effectiveness of a comprehensive management program for elderly patients with chronic cardiovascular diseases (CVDs). The program integrates pharmacological treatment, lifestyle modification, health education, and long-term follow-up, with enhanced monitoring using 7-day ECG recording. The study focuses on major chronic CVDs including hypertension, coronary artery disease, atrial fibrillation, and heart failure. Approximately 30,000 participants aged ≥60 years will be enrolled and followed for up to 10 years.
With the acceleration of global population aging, older adults have become the primary population at high risk for chronic cardiovascular diseases (CVD). Cardiovascular disease is one of the leading causes of mortality and disability worldwide, and its prevalence and associated disability are markedly higher among the elderly compared to younger age groups. According to data from the World Health Organization (WHO), CVD accounts for approximately 31% of global deaths, with older adults carrying a substantial proportion of this burden.
Due to age-related physiological changes, the presence of multiple comorbidities, and lifestyle factors, elderly individuals often face more complex health challenges. In this population, chronic hypertension, coronary artery disease, heart failure, and diabetes are highly prevalent and frequently coexist. These conditions tend to be chronic, progressive, and involve multiple organ systems, further complicating disease management. Moreover, elderly patients often experience poor drug tolerance, multiple complications, and impaired quality of life, which necessitate not only more refined clinical interventions but also individualized management strategies tailored to patient-specific needs.
Traditional single-disease treatment strategies are often insufficient to address the multifaceted needs of elderly patients with chronic cardiovascular diseases. Existing evidence suggests that comprehensive management models-integrating multidisciplinary collaboration, personalized treatment, long-term follow-up, and health education-can significantly improve cardiovascular outcomes, reducing hospitalization rates, mortality, and other adverse events. However, systematic research on comprehensive management in elderly populations remains limited. Most current studies focus on specific diseases or therapeutic approaches, lacking multidimensional assessment and intervention strategies.
Therefore, the present study aims to establish a comprehensive management cohort for chronic cardiovascular diseases in elderly populations, in order to explore how integrated management strategies influence cardiovascular health in real-world settings. This study will evaluate the effectiveness of such approaches in reducing cardiovascular events and mortality, thereby providing scientific evidence and guidance for future clinical practice. The Qujiang Project Team of the National Clinical Research Center for Cardiovascular Diseases will undertake this study.
Community-dwelling elderly residents of Qujiang District with chronic cardiovascular diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age ≥60 years
Resident of Qujiang District
Diagnosed with chronic CVD (hypertension, coronary artery disease, heart failure, atrial fibrillation, or others)
Able and willing to provide
Exclusion Criteria
Severe cognitive impairment or inability to provide consent
\<1 year due to non-cardiovascular disease
Participation refusal
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up) Enhanced monitoring with 7-day ECG
Incidence of cardiovascular events
Incidence of cardiovascular events (myocardial infarction, stroke, hospitalization for heart failure, cardiovascular death) - assessed annually during follow-up
Time frame: 10 years
All-cause and cardiovascular mortality
All-cause and cardiovascular mortality - assessed at 10 years
Time frame: 10 years
Hospitalization rates
Hospitalization rates (number and duration of hospitalizations for CVD-related causes)
Time frame: 10 years
Atrial fibrillation burden
Atrial fibrillation burden - time proportion of AF episodes, number of episodes, longest episode duration (measured during 7-day ECG monitoring in the blanking period and annually thereafter)
Time frame: 10 years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Mar 2035, 132 months after the start.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 132 months is above that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.